Related Experiment Videos
[Chemodenervation with botulinumtoxin in masseteric hypertrophy]
R A Mischkowski1, M Siessegger, F Lazar
1Klinik und Poliklinik für Zahnärztliche Chirurgie und für Mund-, Kiefer- und Plastische Gesichtschirurgie, Universität zu Köln. r.mischkowski@uni-koeln.de
Mund-, Kiefer- Und Gesichtschirurgie : MKG
|February 16, 2005
Summary
Botulinum toxin serotype A injections effectively treat masseteric hypertrophy, reducing muscle size and improving facial symmetry. This study found no complications, establishing it as a preferred treatment for this condition.
Area of Science:
- Medical aesthetics
- Plastic surgery
- Neurology
Context:
- Masseteric hypertrophy involves enlargement of the masseter muscle, impacting facial appearance.
- Treatment options vary from conservative methods to surgical interventions.
- Botulinum toxin serotype A is explored as a minimally invasive therapeutic option.
Purpose:
- To evaluate the efficacy and safety of botulinum toxin serotype A for treating masseteric hypertrophy.
- To assess the impact of botulinum toxin on facial asymmetry and muscle mass reduction.
Summary:
- Eight patients with masseteric hypertrophy received botulinum toxin injections.
- All patients experienced significant improvement in facial asymmetry due to muscle mass reduction.
- No complications, side effects, or treatment failures were reported.
Impact:
- Botulinum toxin injections offer a safe and effective non-surgical treatment for masseteric hypertrophy.
- This approach provides a viable alternative to surgical ablation.
- The findings support botulinum toxin as a first-line therapy for masseteric hypertrophy.